Federal Rescheduling Inflection: Tax Relief Could Add $1.2B to MSO EBITDA by 2027
The Numbers: Tax Relief as a Margin Catalyst
Section 280E—the IRS rule banning tax deductions for cannabis operators—has been a silent profit-killer since state legalization began. At current taxation rates, the Big 5 MSOs collectively pay ~$280-320M annually in unnecessary tax drag. That’s margin that should be flowing to EBITDA and buybacks.
Recent Congressional moves signal real momentum:
- HR 7277 now has 52 co-sponsors (up from 31 in Q4 2025)
- Senate companion gaining traction with bipartisan support
- Probability estimate: 40-50% of passage within 18 months (per political betting markets)
For CURLF (Curaleaf), TCNNF (Trulieve), and GTBIF (Green Thumb), this translates to:
- Curaleaf: +$120-140M annual EBITDA if relief passes
- Trulieve: +$110-130M annual EBITDA
- Green Thumb: +$80-100M annual EBITDA
Schedule III Reclassification: The Regulatory Tailwind
Parallel to the tax reform push, the DEA’s ongoing Schedule III review for cannabis derivatives (like CBD and minor cannabinoids) continues gaining speed. A Schedule III move would unlock:
- National banking access for qualifying operators
- Federal research licenses for medical cannabinoid programs
- Easier interstate commerce for hemp-derived products
CRLBF (Cresco Labs) and VRNO (Verano) are particularly well-positioned to benefit from interstate harmonization, as both have significant hemp-derived cannabinoid operations.
Wall Street’s Mispricing: The Catalyst Setup
Current MSO valuations embed only ~25% probability of federal tax relief. But political momentum, bipartisan support, and investor pressure suggest the real probability is closer to 45-55%. That’s a classic catalyst setup.
The math: If a 20-30% probability repricing occurs before year-end, you could see 15-25% upside on the Big 5 operators before any actual legislative passage.
What to Watch
- House Ways & Committee vote on HR 7277 (expected July-August)
- Senate Judiciary Committee schedule for Schedule III review
- MSO earnings calls for 280E commentary and tax guidance
- Political betting odds on cannabis reform passage
The Bottom Line
Tax relief isn’t a moonshot—it’s increasingly likely. And the market isn’t fully pricing it in. For investors in CURLF, TCNNF, GTBIF, CRLBF, and VRNO, this is a meaningful tail risk to your upside.
By Sheeba M. | Weedstock Cannabis Market Intelligence
Sources: Congressional Research Service (HR 7277 tracking), DEA Scheduling Review (2026 Q2 updates), MSO earnings transcripts (Q1 2026), Political Betting Markets (PredictIt, Polymarket cannabis reform odds)